SecBot SecBot
PRESS-RELEASE ·Filed May 26, 2026

ESPR

Esperion Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

These are supportive clinical data but not a near-term catalyst, the Phase 3 pediatric studies are still ongoing, and no regulatory filing was announced. The 42% ≥30% LDL-C reduction in CLEAR Outcomes is an incremental positive for the product's on-label messaging. Expect limited stock reaction unless subsequent regulatory news (FDA sNDA filing for pediatric indication) emerges. If you have a position, wait for concrete regulatory milestones.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$3.12
T+0 close · May 26, 2026 · via day close
Latest settled
+0.96%
T+20 · $3.15
Vs SPY
+2.91%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 26 $3.12entry
  2. T+1 · 6mo ago +0.32%α +0.31% · $3.13
  3. T+5 · 6mo ago +0.32%α −0.76% · $3.13
  4. T+20 · 5mo ago +0.96%α +2.91% · $3.15
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid reduced LDL-C in children (range 6-25%) without new safety concerns, and that 42% of statin-intolerant adults achieved ≥30% LDL-C reduction. These data support ongoing Phase 3 pediatric studies and reinforce the product profile, but are interim scientific presentations without a hard regulatory catalyst or financial update.

Key Facts

  • Phase 2 study in children aged 6-17 with HeFH showed weight-based bempedoic acid dosing produced adult-equivalent exposure and LDL-C reductions of 6-25% with no new safety signals.
  • CLEAR Outcomes post-hoc analysis: 42% of statin-intolerant adults on bempedoic acid achieved ≥30% LDL-C reduction at 3 months, comparable to moderate-intensity statins.
  • Factors associated with ≥30% LDL-C reduction included female sex, higher baseline LDL-C, and concurrent ezetimibe use.
  • No new regulatory approvals, label expansions, financial results, or guidance were announced in this press release.

Financial Impact

No financial figures disclosed; data support potential label expansion to pediatric population and commercial differentiation.

Risk Factors

  • Phase 3 pediatric study results could differ from Phase 2, delaying or preventing label expansion.
  • Competition from newer non-statin LDL-C therapies (e.g., PCSK9 inhibitors, oral siRNA) could pressure commercial adoption.
  • Esperion remains dependent on single-drug revenue; a pipeline setback would be disproportionately impactful.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300994

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026